NASDAQ:ECYT - Endocyte Stock Price, Price Target & More

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

Endocyte, Inc. (NASDAQ:ECYT) released its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative net margin of 70,510.81% and a negative return on equity of 34.20%. View Endocyte's Earnings History.

4 equities research analysts have issued twelve-month target prices for Endocyte's stock. Their predictions range from $7.00 to $7.00. On average, they expect Endocyte's share price to reach $7.00 in the next year. View Analyst Ratings for Endocyte.

Some companies that are related to Endocyte include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Clovis Oncology (CLVS) and Akcea Therapeutics (AKCA).

Headlines about ECYT stock have been trending positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endocyte earned a news impact score of 0.28 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.34 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Endocyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (8.19%), VHCP Management II LLC (6.19%), BlackRock Inc. (2.48%), Rock Springs Capital Management LP (0.97%), Eventide Asset Management LLC (0.50%) and Millennium Management LLC (0.27%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.

ECYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.

ECYT stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, VHCP Management II LLC, Rock Springs Capital Management LP, BlackRock Inc., Eventide Asset Management LLC, Tibra Equities Europe Ltd, Baird Financial Group Inc. and Element Capital Management LLC. View Insider Buying and Selling for Endocyte.

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ECYT stock can currently be purchased for approximately $14.12.

Endocyte has a market capitalization of $983.45 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.